Gotham Asset Management LLC Grows Stake in Pfizer Inc. $PFE

Key Points

• Gotham Asset Management LLC significantly increased its stake in Pfizer Inc. by 204.1% in Q1, acquiring 287,925 additional shares, bringing its total holdings to 428,965 shares valued at approximately $10.87 million.
• Pacer Advisors Inc. and Amundi also made substantial increases to their stakes in Pfizer, with Pacer's position growing by 856.8% and Amundi's by 43.4%.
• Pfizer reported an earnings per share (EPS) of $0.78 for the last quarter, exceeding analyst expectations of $0.58, alongside a revenue of $14.65 billion, indicating a year-over-year growth of 10.3%.

Gotham Asset Management LLC increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 204.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 428,965 shares of the biopharmaceutical company's stock after acquiring an additional 287,925 shares during the period. Gotham Asset Management LLC's holdings in Pfizer were worth $10,870,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. grew its position in Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Amundi grew its holdings in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new position in Pfizer during the 1st quarter valued at about $389,861,000. Starboard Value LP purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $407,730,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after buying an additional 9,041,990 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.3%

Shares of NYSE PFE opened at $24.86 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $141.31 billion, a price-to-earnings ratio of 13.22, a PEG ratio of 0.88 and a beta of 0.55. The stock has a 50 day moving average price of $24.85 and a 200 day moving average price of $24.35. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer's dividend payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. HSBC dropped their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group boosted their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.